SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech - Quaterly Results

08 Nov 2022 Evaluate
The company witnessed a 15.17% growth in the revenue at Rs. 1327.30 millions for the quarter ended September 2022 as compared to Rs. 1152.52 millions during the year-ago period.The company has announced a 46.64% increase in its profits to Rs . 122.09  millions for the  quarter ended September 2022 compared to Rs. 83.26 millions in the corresponding quarter in the previous year.Operating profit surged to 186.70 millions from the corresponding previous quarter of 144.01 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1327.30 1152.52 15.17 2526.66 2262.08 11.70 4659.30 4276.02 8.96
Other Income 26.11 12.19 114.19 54.69 19.08 186.64 67.06 30.94 116.74
PBIDT 186.70 144.01 29.64 353.20 274.75 28.55 596.01 577.86 3.14
Interest 1.15 4.36 -73.62 4.65 9.18 -49.35 14.17 12.90 9.84
PBDT 185.55 139.65 32.87 348.55 265.57 31.25 581.84 241.45 140.98
Depreciation 29.05 30.75 -5.53 56.61 61.00 -7.20 121.47 129.65 -6.31
PBT 156.50 108.90 43.71 291.94 204.57 42.71 460.37 111.80 311.78
TAX 34.41 25.64 34.20 71.85 54.44 31.98 74.76 61.70 21.17
Deferred Tax -2.86 -2.12 34.91 -1.90 -2.19 -13.24 -26.57 13.28 -300.08
PAT 122.09 83.26 46.64 220.09 150.13 46.60 385.61 50.10 669.68
Equity 108.97 108.97 0.00 108.97 108.97 0.00 108.97 64.11 69.97
PBIDTM(%) 14.07 12.50 12.57 13.98 12.15 15.09 12.79 13.51 -5.34

Windlas Biotech Share Price

865.40 -6.35 (-0.73%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×